ResMed Inc. RMD
Composite 62/100; the shares have moved about 33% annualised. Names that move more contribute more risk for the same amount invested, and our composite reflects how strong the evidence for this one is right now.
Momentum ranks 34/100 — a moderate mark against it.
Balance-sheet strength ranks 92/100 — a strong point in its favour. Quality ranks 74/100 — a moderate point in its favour. Growth ranks 57/100 — a slight point in its favour.
Momentum ranks 34/100 — a moderate mark against it. Valuation ranks 46/100 — a slight mark against it.
What the company does ResMed designs and sells cloud-connected medical devices for sleep and respiratory care, including diagnostic tools like ApneaLink Air and NightOwl, and remote monitoring systems such as AirView and myAir. Its software segment (Brightree) serves residential care providers. The company generates revenue through device sales, recurring cloud services, and patient engagement tools.
Key financials ResMed reports strong profitability with ROE 24.3%, ROA 14.0%, and ROCE 25.7%. Gross margins are 61.6%, operating margins 31.0%, and net margins 27.0%. Revenue and EPS growth stand at 9.8% and 10.5%, respectively. The balance sheet is healthy with a debt/equity ratio of 0.13 and net debt/EBITDA of -0.31.
Stock health SiderAxia scores show strong quality (77.5) and strength (89.8), but weak momentum (33.1) and income (46.4). The Piotroski F-Score is 6/9 and Altman Z is 11.16, indicating low bankruptcy risk. The current ratio is 3.10, and interest coverage is 39.04x.
Price vs fair value ResMed trades at a discount of 4.50% versus the analyst mean target of 247.20 (Barchart). - Forward P/E of 18.87 is below the trailing P/E of 21.64, suggesting valuation support. - PEG of 1.29 indicates fair growth-adjusted pricing. - Recent 1-day gain of 1.78% and 3-month momentum of 14.08% reflect short-term sentiment.
Looking forward Forward PEG of 1.29 and EV/EBITDA of 14.45 suggest balanced valuation relative to growth. Analysts highlight cloud-connected device adoption as a key driver, though momentum remains weak over 6-12 months. The company’s recurring revenue model and strong margins position it well for long-term stability.
This is not investment advice. Sideravia provides automated, data-driven analysis for information and education only. Nothing on this page is a personal recommendation or an invitation to buy or sell any security, and it does not consider your objectives or financial situation. Assessments are generated by rules applied uniformly to every covered stock — how our scores work.
Data as of 2026-09-05, compiled from third-party sources; errors and delays are possible and figures are not warranted. Investing puts your capital at risk; past performance does not predict future results. We publish our full track record, including the calls that lost, and our conflicts of interest.